Pipeline

Addressing a range of degenerative retinal diseases

Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics​

Indication

Product Candidate

Discovery

Ind enabling phase

Phase 1

Retinitis Pigmentosa

Genotype agnostic

RTx-015

IND Enabling Phase

Other Inherited retinal degenerations

Stargardt’s disease

RTx-015

IND Enabling Phase

Geographic Atrophy

RTx-021

Discovery